Palmas A, Tefferi A, Myers JL, Scott JP, Swensen SJ, Chen MG et al. Bronchiolitis obliterans organizing pneumonia and chronic graft-versus-host disease in a child after allogeneic bone marrow transplantation. Kleinau I, Perez-Canto A, Schmid HJ, Grassot A, Staab D, Renz H et al. Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. Kanda Y, Takahashi T, Imai Y, Miyagawa K, Ohishi N, Oka T et al. Clinical features of allogeneic hematopoietic stem cell transplantation-associated organizing pneumonia. Jinta M, Ohashi K, Ohta T, Ieki R, Abe K, Kamata N et al. Association between acute and chronic graft-versus-host disease and bronchiolitis obliterans organizing pneumonia in recipients of hematopoietic stem cell transplants. Hum Pathol 1995 26: 668–675.įreudenberger TD, Madtes DK, Curtis JR, Cummings P, Storer BE, Hackman RC. The histological spectrum of pulmonary graft-versus-host disease in bone marrow transplant recipients. A report of 25 cases and a review of the literature. Thorax 2000 55: 318–328.Īlasaly K, Muller N, Ostrow DN, Champion P, FitzGerald JM. Semin Respir Crit Care Med 2005 26: 482–489.Ĭordier JF. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant. Bronchiolitis obliterans syndrome (BOS), bronchiolitis obliterans organizing pneumonia (BOOP), and other late-onset noninfectious pulmonary complications following allogeneic hematopoietic stem cell transplantation. Yoshihara S, Yanik G, Cooke KR, Mineishi S. Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Eur Respir J 2002 19: 794–796.Īfessa B, Litzow MR, Tefferi A. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias.
Prospective studies are required to elucidate the true risk factors for COP/BOOP and to develop a prophylactic approach.ĭemedts M, Costabel U. Allogeneic immunity and conditioning toxicity could be associated with COP/BOOP. Pulmonary failure and fatal infection accounted for 41% ( n=19) and 26% ( n=12) of the non-relapse death.
Of the 193 patients with COP/BOOP, 77 died, including non-relapse death in 46 (59%). On the other hand, BU-based myeloablative conditioning (OR 0.52, P=0.033), or fludarabine-based reduced-intensity conditioning (OR 0.50, P=0.0011) in comparison with a TBI-based regimen and in vivo T-cell depletion (OR 0.46, P=0.055) were associated with a lower risk. HLA disparity (odds ratio (OR) 1.51, P=0.05), female-to-male HCT (OR 1.53, P=0.023), and PBSC transplant (OR 1.84, P=0.0076) were significantly associated with an increased risk of COP/BOOP. Among 9550 eligible recipients, 193 experienced COP/BOOP (2%). Therefore, we identified the pre-transplant risk factors for the development of COP/BOOP using the Japan transplant registry database between 20. However, the pathogenesis of this complication has not yet been elucidated. Cryptogenic organizing pneumonia (COP), previously known as bronchiolitis obliterans organizing pneumonia (BOOP), is a significant complication after allogeneic hematopoietic SCT (HCT).
0 kommentar(er)
